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Impaired Endothelial Function of the Retinal Vasculature in
Hypertensive Patients
Christian Delles, MD; Georg Michelson, MD; Joanna Harazny, PhD; Sebastian Oehmer, MD;
Karl F. Hilgers, MD; Roland E. Schmieder, MD, FACC
Background and Purpose—Arterial hypertension constitutes a central factor in the pathogenesis of stroke. We examined
endothelial function of the retinal vasculature as a model of the cerebral circulation.
Methods—Thirty-eight young subjects (19 hypertensive and 19 normotensive) were treated with the AT1-receptor blocker
candesartan cilexetil and placebo, each over 7 days. Retinal capillary flow and blood flow velocity in the central retinal
artery were assessed with scanning laser Doppler flowmetry and pulsed Doppler ultrasound, respectively. NG-mono-
methyl-L-arginine (L-NMMA) was infused to inhibit nitric oxide (NO) synthesis. Diffuse luminance flicker was applied
to stimulate NO release.
Results—In normotensive subjects, L-NMMA decreased retinal capillary flow by 8.2%13% (P0.05) and flickering
light increased mean blood flow velocity in the central retinal artery by 19%29% (P0.01). In contrast, no significant
change to these provocative tests was seen in hypertensive subjects. Treatment with candesartan cilexetil restored a
normal pattern of reactivity in retinal capillaries (L-NMMA: decrease in perfusion by 10%17%, P0.05) and the
central retinal artery (flicker: increase in mean blood flow velocity by 42%31%, P0.001) in hypertensive patients.
Conclusions—Endothelial function of the retinal vasculature is impaired in early essential hypertension but can be
improved by AT1-receptor blockade. (Stroke. 2004;35:1289-1293.)
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Arterial hypertension is the predominant risk factor forischemic stroke.1 Apart from the level of blood pressure,
nonhemodynamic factors including the renin-angiotensin-al-
dosterone system contribute to the risk of stroke and to infarct
size. In animal models of ischemic stroke, therapy with
angiotensin II subtype 1 receptor (AT1-receptor) blockers
improved survival.2 In accordance, treatment with the AT1-
receptor blocker losartan reduces the risk of stroke in patients
with arterial hypertension.3
AT1-receptor blockers improve endothelium-dependent va-
sodilation in patients with arterial hypertension.4 In humans,
the reduction in blood flow in response to nitric oxide
synthase inhibitors has been used as a surrogate for the
contribution of nitric oxide to the maintenance of perfusion in
various vascular beds, including the forearm and the renal
circulation, by us and others.4–6
The retinal vasculature is morphologically and functionally
related to the cerebral vessels because of the common origin
from the internal carotid artery. Recently, noninvasive tech-
niques to measure retinal perfusion in humans have been
developed,7,8 making the retinal vascular a useful model to
obtain insight into endothelial function of the cerebral circu-
lation. We conducted the present study to test the hypotheses
that endothelium-dependent vasodilation of the retinal vascu-
lature is already impaired in early essential hypertension and
that it can be restored by AT1-receptor blockade.
Subjects and Methods
Study Participants
Study participants were screened for normal or mildly elevated blood
pressure according to World Health Organization recommendations.
Inclusion criteria were male gender and age between 18 and 35
years. Exclusion criteria were renal, hepatic, and any cardiovascular
disease other than mild-to-moderate arterial hypertension (defined as
140 mm Hg  systolic blood pressure 200 mm Hg and
90 mm Hg  diastolic blood pressure 110 mm Hg, or both); eye
disease other than grade I hypertensive retinopathy; any evidence of
secondary hypertension; and any current cardiovascular medication
(including antihypertensive medication). Regular smokers were not
included; however, 4 subjects sporadically smoked cigarettes (up to
5 per month; none of the participants was allowed to smoke on the
day of or the day before the retinal examination) and 3 subjects
stopped smoking at least 1 year ago. Written consent was obtained
before study inclusion. Two participants withdrew their consent after
double-blind study medication had been distributed. Thus, 38 sub-
jects (19 normotensives and 19 hypertensives) were examined.
Clinical characteristics are given in Table 1.
Study Design
The study protocol was approved by the Clinical Investigation Ethics
Committee of the University of Erlangen-Nu¨rnberg. After inclusion
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into this double-blind, randomized, crossover trial, study medication
was distributed according to the randomization list. Participants were
advised to take 1 tablet of study medication (either 16 mg of
candesartan cilexetil or placebo) each morning for 7 days. On day 7,
measurements of retinal perfusion were performed during the after-
noon between 2 and 4 PM. After a 2-week washout phase, the second
course of randomized study medication (either placebo or 16 mg of
candesartan cilexetil) had to be taken for 7 days. A second measure-
ment of retinal perfusion was performed on day 7.
The placebo-controlled crossover design enabled us to take
hemodynamic data from the placebo phase as baseline perfusion
parameters for comparison between normotensive and hypertensive
subjects. The examiner performing the measurement of retinal
perfusion (J.H.) was blinded to the participants’ blood pressure
status.
Experimental Protocol for the Measurement of
Retinal Perfusion
In the first test, blood flow velocity in the central retinal artery was
measured in the supine position after 30 minutes of rest at baseline,
during flicker light stimulation (10 Hz; Photo Stimulator 750,
Siemens-Elema AB; recordings started 5 to 20 seconds after the start
of luminance flicker), and 10 to 15 minutes after flicker light
exposure to ensure that blood flow velocity has returned to baseline
values. Flickering light increases retinal blood flow via a nitric
oxide-dependent mechanism.8,9
In the second test, baseline retinal capillary flow was measured in
the sitting position. The nitric oxide synthase inhibitor, NG-mono-
methyl-L-arginine (L-NMMA; 3 mg per kg of body weight; Clinalfa)
was administered intravenously as a bolus infusion over 5 minutes.
Immediately after L-NMMA infusion, retinal capillary flow was
measured again.10,11
Measurement of Retinal Capillary Flow
Retinal capillary blood flow was assessed using scanning laser
Doppler flowmetry at 670 nm (Heidelberg Retina Flowmeter, Hei-
delberg Engineering) as previously described in detail.7 Briefly, the
Doppler shift in a retinal sample of 2.560.640.30 mm was
scanned within 2 seconds at a resolution of 256 points64 lines
128 lines. The confocal technique of the device ensured that only the
capillary flow of the superficial retinal layer of 300 m was
measured. Measurements were performed in the juxtapapillary area
of the right eye, 2 to 3 mm temporally to the optic nerve; the mean
from 3 measurements was taken. Analysis of perfusion images was
performed offline with automatic full-field analysis (Figure 1; SLDF
version 3.3, Heidelberg Engineering).7 This led to a perfusion map
excluding vessels with a diameter 30 m, without lines with
saccades, and without pixels with inadequate reflectivity. The mean
retinal capillary flow was calculated in the area of interest and
expressed as arbitrary units.
Measurement of Blood Flow Velocity in the
Central Retinal Artery
Blood flow velocity in the right central retinal artery was measured
using pulsed Doppler sonography at 4 MHz (EME Companion,
Nicolet Biomedical Inc) with a 10-mm Doppler probe as previously
described.8 The mean measuring depth was 304 mm, with a gate
(measuring distance) of 5 mm. Measurements were performed while
the subjects’ eyes were open. At least 10 pulse curves were averaged
for quantitative analysis using an automated computer analysis
(Flicker version 1.0, JT Harazny).
Statistical Analysis
All statistical analysis was performed using SPSS software (release
10.0, SPSS Inc). Significant deviations from normal distribution
were excluded by the Kolmogorov-Smirnov test. Paired and un-
paired Student t tests were used for comparisons when appropriate.
A 2-tailed P0.05 was considered to be significant. All values are
expressed as meanstandard deviation.
Results
Systemic and Retinal Hemodynamics in
Normotensive and Hypertensive Subjects
At baseline, in the placebo phase, blood pressure was
significantly different between normotensive and hyper-
tensive study participants (1246/717 versus 13711/
817 mm Hg, P0.01). In contrast, parameters for blood
flow velocity in the central retinal artery and retinal
capillary flow were similar across the groups (Table 2).
In normotensive subjects, L-NMMA significantly de-
creased retinal capillary flow already in the placebo phase by
8%13% (P0.05) (Figure 1). In contrast, L-NMMA had no
significant effect on retinal capillary flow in hypertensive
patients (Table 2). In normotensive subjects, L-NMMA in-
creased mean arterial blood pressure by 3.93.7 mm Hg
(P0.001) and decreased heart rate by 116 minutes1
(P0.001). In hypertensive subjects, L-NMMA decreased
heart rate by 117 minutes1 (P0.001) but had no signifi-
cant effect on mean arterial blood pressure (increase by
1.38.9 mm Hg, PNS).
In normotensive subjects, flickering light significantly
increased blood flow velocity in the central retinal artery in
the placebo phase by 21%29% (P0.001). In contrast,
flickering light had no significant effect on blood flow
TABLE 1. Clinical Characteristics
Normotensives
n19
Hypertensives
n19
Age (y) 274 284
Weight (kg) 788 8011
Height (m) 1.830.06 1.810.08
Body surface area (m2) 2.000.12 2.000.16
Body mass index (kg/m2) 23.31.6 24.42.7
Systolic blood pressure (mm Hg) 12610 1469†
Mean arterial blood pressure (mm Hg) 957 1125†
Diastolic blood pressure (mm Hg) 797 9014*
*†Significant differences between normotensive and hypertensive subjects.
*P0.01. †P0.001.
Figure 1. Assessment of retinal capillary perfusion by scanning
laser Doppler flowmetry. a and b, Reflection images. c and d,
Perfusion images. e and f, Perfusion images for automatic full-
field analysis. Left images (a, c and e) were obtained at base-
line, and right images (b, d and f) were obtained after infusion of
L-NMMA. For better understanding, a larger arteriole is shown
demonstrating the reduction in flow through L-NMMA (d vs c).
For assessment of retinal capillary flow, such larger vessels are
excluded for analysis.
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velocity in the central retinal artery in hypertensive patients
(Table 2). Flicker light stimulation had no significant effect
on blood pressure in normotensive and hypertensive subjects.
Effect of AT1-Receptor Blockade on Systemic and
Retinal Hemodynamics
At baseline, candesartan cilexetil significantly decreased
systolic (P0.05) and diastolic blood pressure (P0.01) in
hypertensive patients and diastolic blood pressure (P0.01)
in normotensive subjects (Table 3).
Candesartan cilexetil decreased mean blood flow velocity
in the central retinal artery in the normotensive and hyper-
tensive study participants (both P0.05). Retinal capillary
flow significantly decreased in normotensive subjects only
(P0.01) (Table 3).
In normotensive subjects, the response of retinal capillary
flow to L-NMMA was not different between the placebo and
the candesartan cilexetil phase. In contrast, the response of
retinal capillary flow to L-NMMA was enhanced by cande-
sartan cilexetil in hypertensive patients (from 317 to
1017%; P0.01) (Table 4, Figure 2).
Treatment with candesartan cilexetil did not change the
response of blood flow velocity in the central retinal artery to
flicker light stimulation in normotensive subjects. In contrast,
treatment with candesartan cilexetil markedly increased the
response of blood flow velocity in the central retinal artery to
flicker light stimulation in hypertensive patients (mean blood
flow velocity: from 5%37% to 40%31%; P0.05),
thereby restoring the physiological response pattern (Table 4).
Discussion
Improvement of Endothelial Function by
Candesartan Cilexetil
In young patients with essential hypertension without any
hypertension-related end-organ damage, we found that retinal
perfusion parameters are similar to those in normotensive
control subjects. With resting and casual blood pressures
being greater in hypertensive than in normotensive subjects,
this indicates an already increased retinal vascular resistance
in our hypertensive subjects. In accordance, the blunted
response of retinal capillary flow to L-NMMA in hyperten-
sive subjects indicates a reduced contribution of nitric oxide
to the maintenance of retinal perfusion. Our data in hyper-
tensive patients are in accordance with data in patients with
type 1 diabetes in whom a reduced response of choroidal
circulation to L-NMMA has been observed.12
Therapy with the AT1-receptor blocker candesartan cilex-
etil restored both the contribution of nitric oxide to the
maintenance of retinal perfusion and nitric oxide-dependent
vasodilation in the retinal vasculature of patients with arterial
hypertension. This increase in nitric oxide bioavailability in
hypertensive patients appears to outweigh a possible reduc-
tion in retinal perfusion caused by the blood pressure-
lowering effect of candesartan cilexetil, because in contrast to
normotensive subjects, retinal capillary flow did not decrease
in the candesartan cilexetil phase in hypertensive patients.
An increase in nitric oxide bioavailability and restoration
of impaired endothelium-dependent vasodilation through
TABLE 2. Effects of Flickering Light and L-NMMA on Retinal Perfusion
Normotensives n19 Hypertensives n19
Baseline Flicker Baseline Flicker
Peak systolic blood flow velocity in the CRA (%) 11.31.8 12.72.5* 10.91.8 11.62.5
End-diastolic blood flow velocity in the CRA (%) 3.90.8 5.01.2† 4.41.1 4.81.3
Mean blood flow velocity in the CRA (%) 6.61.0 7.81.7† 6.91.3 7.32.0
Baseline L-NMMA Baseline L-NMMA
Retinal capillary perfusion (AU) 37264 34047* 36577 37388
L-NMMA indicates N G-monomethyl-L-arginine; CRA, central retinal artery; AU, arbitrary units.
Data are given for the placebo phase (baseline values).
*†Significant changes through flickering light or L-NMMA. *P0.05. †P0.01.
TABLE 3. Effect of Candesartan Cilexetil on Systemic and Retinal Hemodynamics
Normotensives n19 Hypertensives n19
Placebo
Candesartan
Cilexetil Placebo
Candesartan
Cilexetil
Systolic blood pressure at rest (mm Hg) 1246 12210 13711 1328*
Mean arterial blood pressure at rest (mm Hg) 927 908 1038 1016
Diastolic blood pressure at rest (mm Hg) 717 679† 817 758†
Peak systolic blood flow velocity in the CRA (cm/s) 11.31.8 10.61.0 10.91.8 10.41.5
End-diastolic blood flow velocity in the CRA (cm/s) 3.90.8 3.80.6 4.41.1 3.80.6†
Mean blood flow velocity in the CRA (cm/s) 6.61.0 6.10.7* 6.91.3 6.21.0*
Retinal capillary flow (AU) 37266 32655† 36577 39784
*†Significant changes between the candesartan cilexetil and the placebo phase.
*P0.05. †P0.01.
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AT1-receptor blockers has already been found in various
vessel beds, including the forearm, coronary, and renal
circulation.4,13–15 Potential mechanisms include reduced for-
mation of reactive oxygen species through blockade of the
AT1-receptor and increased nitric oxide synthesis through
stimulation of AT2-receptors by endogenous angiotensin
II.16,17 However, the effects of AT1-receptor blockade on the
endothelium function of human retinal vasculature have not
yet been examined, although regional disparities of nitric
oxide bioavailability between vascular beds have been
described.18–20
Endothelial Function of the Human
Cerebral Circulation
The main reason for this lack of knowledge about endothelial
function of the human cerebral circulation so far has been the
limited access for measurement. Alternatively, the retinal
circulation constitutes an ideal model to examine the regula-
tion of cerebral blood flow. According to previous experi-
ments, nitric oxide plays an important role in the regulation of
retinal21,22 and cerebral blood flow.23,24 Nitric oxide defi-
ciency contributes to the enlarged cerebral infarct size in
L-NMMA–treated rats.25 Furthermore, the renin-angiotensin-
aldosterone system substantially contributes to stroke devel-
opment and infarct size. In animal models of ischemic stroke,
AT1-receptor blockers reduce the volume of total and cortical
infarcts, reduce the decrease in cerebral blood flow at the
peripheral area of ischemia, and improve survival.2,26,27 In
AT1-receptor–deficient mice, the infarct size after experimen-
tally induced cerebral ischemia is smaller than in wild-type
mice.28 The AT1-receptor blocker candesartan cilexetil pre-
vents against brain edema in stroke-prone spontaneously
hypertensive rats.29 In patients with arterial hypertension,
AT1-receptor blockade at similar blood pressure control was
superior to beta-receptor blockade to prevent the incidence of
stroke.3 Our present data point to a link between the renin-
angiotensin-aldosterone system and endothelium-dependent
vasodilation of the retinal and thereby the cerebral
vasculature.
Limitations
Three limitations of our study have to be discussed. First,
comparison of baseline perfusion parameters between normo-
tensive and hypertensive subjects and between the placebo
and verum phases might be influenced by intra-individual
variability of retinal perfusion. However, the response of
retinal perfusion to stimuli such as L-NMMA and flickering
light is less likely influenced by this variability. Second, we
do not know whether our findings will hold true in hyperten-
sive patients with end-organ damage such as a history of
stroke. Third, we are aware of the fact that our study was
placebo-controlled and not controlled against another active
treatment. Although data from other vasculatures demonstrate
superiority of AT1-receptor blockers in terms of improvement
of endothelial function,4,13–15 we do not know whether other
antihypertensive agents improve nitric oxide bioavailability
and nitric oxide-dependent vasodilation of the retinal vascu-
lature, too. However, taken together with experimental and
clinical data, our findings provide a basis for the use of the
AT1-receptor blocker candesartan cilexetil to improve endo-
thelium-dependent vasodilation of the retinal and probably of
the cerebral vasculature in patients with arterial hypertension.
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